Repository logo
 
Publication

Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020

2020-03-12Journal article Open access
Simple item page
dc.contributor.authorRose, Angela
dc.contributor.authorKissling, Esther
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorMcMenamin, Jim
dc.contributor.authorPozo, Francisco
dc.contributor.authorTrebbien, Ramona
dc.contributor.authorMazagatos, Clara
dc.contributor.authorWhitaker, Heather
dc.contributor.authorMachado, Ausenda
dc.contributor.authorGómez, Verónica
dc.contributor.authorNunes, Baltazar
dc.contributor.authorKislaya, Irina
dc.contributor.authorPechirra, Pedro
dc.contributor.authorConde, Patrícia
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorCristóvão, Paula
dc.contributor.authorCosta, Inês
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorEuropean IVE Group
dc.date.accessioned2021-03-05T15:06:03Z
dc.date.available2021-03-05T15:06:03Z
dc.date.issued2020-03-12
dc.description.abstractBackground: Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between September 2019 and January 2020. Aim: To provide interim 2019/20 influenza vaccine effectiveness (VE) estimates from six European studies, covering 10 countries and both primary care and hospital settings. Methods: All studies used the test-negative design, although there were some differences in other study characteristics, e.g. patient selection, data sources, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders. Results: There were 31,537 patients recruited across the six studies, of which 5,300 (17%) were cases with 5,310 infections. Most of these (4,466; 84%) were influenza A. The VE point estimates for all ages were 29% to 61% against any influenza in the primary care setting and 35% to 60% in hospitalised older adults (aged 65 years and over). The VE point estimates against A(H1N1)pdm09 (all ages, both settings) was 48% to 75%, and against A(H3N2) ranged from −58% to 57% (primary care) and −16% to 60% (hospital). Against influenza B, VE for all ages was 62% to 83% (primary care only). Conclusions: Influenza vaccination is of continued benefit during the ongoing 2019/20 influenza season. Robust end-of-season VE estimates and genetic virus characterisation results may help understand the variability in influenza (sub) type-specific results across studies.pt_PT
dc.description.sponsorshipECDC contributed to funding some of the study sites and the coordination of the EU-PC study. WHO/ Europe contributed to funding the EU-H study. Epiconcept contributed to funding the EU-H study.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuro Surveill. 2020 Mar;25(10):2000153. doi: 10.2807/1560-7917.ES.2020.25.10.2000153pt_PT
dc.identifier.doihttps://doi.org/10.2807/1560-7917.ES.2020.25.10.2000153pt_PT
dc.identifier.issn1560-7917
dc.identifier.urihttp://hdl.handle.net/10400.18/7331
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Centre for Disease Prevention and Controlpt_PT
dc.relation.publisherversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000153pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectInfluenzapt_PT
dc.subjectInfluenza vaccinept_PT
dc.subjectEfectivenesspt_PT
dc.subjectMulticentre Studypt_PT
dc.subjectTest-negative Designpt_PT
dc.subjectEfetividadept_PT
dc.subjectI-MOVEpt_PT
dc.subjectEuroEVApt_PT
dc.subjectGripept_PT
dc.subjectEuropept_PT
dc.subjectDeterminantes da Saúde e da Doençapt_PT
dc.subjectObservação e Vigilânciapt_PT
dc.subjectCuidados Saúde Primáriospt_PT
dc.subjectInfecções Respiratóriaspt_PT
dc.subjectPortugalpt_PT
dc.titleInterim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue10pt_PT
oaire.citation.startPage2000153pt_PT
oaire.citation.titleEurosurveillancept_PT
oaire.citation.volume25pt_PT
person.familyNameMachado
person.familyNameGOMEZ TEIXEIRA PINTO
person.familyNameNunes
person.familyNameKislaya
person.familyNamePechirra
person.familyNameGuiomar
person.givenNameAusenda
person.givenNameVERÓNICA DEL PILAR
person.givenNameBaltazar
person.givenNameIrina
person.givenNamePedro
person.givenNameRaquel
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-idFA1B-D68F-2611
person.identifier.ciencia-idAB11-AD48-A8DF
person.identifier.ciencia-idA815-4295-F91D
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.orcid0000-0002-1849-1499
person.identifier.orcid0000-0003-0485-0005
person.identifier.orcid0000-0001-6230-7209
person.identifier.orcid0000-0001-5772-2416
person.identifier.orcid0000-0001-6352-1100
person.identifier.orcid0000-0002-4563-6315
person.identifier.scopus-author-id9133723200
person.identifier.scopus-author-id56442728800
rcaap.embargofctAcesso de acordo com política editorial da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublicationeae04cda-2c73-437b-8666-6593d03aa34d
relation.isAuthorOfPublicationbe4efa0d-49df-4a93-bfdd-b76d9f7bf492
relation.isAuthorOfPublicationcf6a6914-1de2-4c2a-96b1-9d617ca28a15
relation.isAuthorOfPublication5a75eb0b-6f1c-410d-8f19-5d15d31e2b1b
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublication.latestForDiscovery544ad266-0c22-4a50-9ebc-86acc08d6666

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
eurosurv-25-10-4.pdf
Size:
637.41 KB
Format:
Adobe Portable Document Format
Download

Collections

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais